Sensus Healthcare, Inc. (NASDAQ:SRTS) had its price objective increased by Maxim Group from $6.50 to $7.50 in a research note issued to investors on Friday morning. They currently have a buy rating on the stock.
Shares of Sensus Healthcare (NASDAQ SRTS) traded up $0.04 on Friday, reaching $5.89. 10,864 shares of the company’s stock were exchanged, compared to its average volume of 15,661.
Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 3rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.08. The business had revenue of $4.97 million during the quarter, compared to analyst estimates of $4.50 million. Sensus Healthcare had a negative net margin of 17.21% and a negative return on equity of 23.48%. analysts expect that Sensus Healthcare will post -0.33 EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/11/05/sensus-healthcare-inc-srts-given-new-7-50-price-target-at-maxim-group.html.
In other Sensus Healthcare news, insider Richard Golin sold 8,012 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $6.00, for a total transaction of $48,072.00. Following the completion of the sale, the insider now directly owns 976,530 shares in the company, valued at approximately $5,859,180. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Kalman Fishman sold 5,378 shares of the business’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $6.00, for a total transaction of $32,268.00. Following the sale, the insider now owns 990,845 shares of the company’s stock, valued at $5,945,070. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 98,551 shares of company stock valued at $591,306. Company insiders own 41.70% of the company’s stock.
An institutional investor recently bought a new position in Sensus Healthcare stock. B. Riley Financial Inc. bought a new position in Sensus Healthcare, Inc. (NASDAQ:SRTS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 104,794 shares of the company’s stock, valued at approximately $421,000. B. Riley Financial Inc. owned 0.77% of Sensus Healthcare as of its most recent filing with the SEC. Institutional investors and hedge funds own 8.09% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc, formerly Sensus Healthcare, LLC, is a manufacturer of superficial radiation therapy devices. The Company designs, manufactures and markets medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy.
Receive News & Ratings for Sensus Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.